Program
SEP-380135
A development code. Also written as “14C-SEP-380135”.
Its studies are mostly in Schizophrenia, led by Otsuka.
Furthest: phase 1, since Dec 12, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 31 open or running | phase 1since Dec 12, 2025 | Dec 12, 2025 | Dec 2, 2026phase 1 · NCT07455084 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2025First study: phase 1 study in SchizophreniaFirst studyNCT07305779 · 12 enrolled · United States
- Mar 3, 2026Phase 1 study in SchizophreniaNCT07455084 · 8 planned · United States
- Apr 17, 2026Phase 1 study in SchizophreniaNCT07549581 · 43 enrolled · United States
- Oct 16, 2026Primary completion moved from 2026-04-10 to 2026-12-02Date moved laterphase 1 · +8 months · NCT07455084
Ahead
- Dec 2, 2026Primary completion: phase 1 study in SchizophreniaNCT07455084
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07549581Schizophrenia · United States | 1 | Completed | Sep 12, 2025 | 43 |
| NCT07455084Schizophrenia · United States | 1 | Not yet recruiting | Dec 2, 2026 | 8 |
| NCT07305779Schizophrenia · United States | 1 | Completed | May 3, 2025 | 12 |
How it is read
Names in the registry
- “SEP-380135”, 2 entries
- “14C-SEP-380135”, 1 entry
Codes read as this program: SEP380135.
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.